Eye Don’t Believe It Fill Disclosure: weekly roundups are intended to provide a quick introduction to various companies. They are not intended to be deep dives or opinion…
central nervous system disorders
Axsome Therapeutics (AXSM.Q) announced today that its AXS-05 has met primary and key secondary endpoints in the MERIT (Mechanistic Evaluation of Response in TDR) Phase 2 trial. Additionally, the…
Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according…